|
|
|||||||||||||||||||||||||
|
Acasti Pharma Inc (ACST) Acasti Pharma is a biopharmaceutical company that is focused on developing and commercializing products for rare and orphan diseases by using its drug delivery technologies. Co.'s primary drug candidate, GTX-104, is an IV formulation of nimodipine designed to treat subarachnoid hemorrhage, a rare brain disorder. Co.'s other drug candidates are: GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia, an orphan pediatric genetic neurodegenerative disorder in young children; and GTX-101, which is a topical bioadhesive film-forming bupivacaine spray for Postherpetic Neuralgia, which causes debilitating pain following infection by the shingles virus.
|
|
|||||||||||||||||||||||||
Free ACST Email Alerts:
Acasti Pharma Inc (ACST) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.